Chemotherapy of secondary leukemias

Leukemia and Lymphoma

Volumn 37, Issue 5-6, 2000, Pages 543-549

  Visani, Giuseppe ^a   Pagano, Livio ^b   Pulsoni, Alessandro ^b   Tosi, Patrizia ^b   Piccaluga, Pier Paolo ^b   Pastano, Rocco ^b   Grafone, Tiziana ^b   Malagola, Michele ^b   Isidori, Alessandro ^b   Tura, Sante ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

Chemotherapy; Cytogenetics; Leukemia; Secondary

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; LOMUSTINE; MELPHALAN; MITOXANTRONE; PROCARBAZINE; SEMUSTINE; TENIPOSIDE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER RADIOTHERAPY; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CYTOPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; METASTASIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; ACUTE DISEASE; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; RADIOTHERAPY; REVIEW; SALVAGE THERAPY; SECOND CANCER; ULTRASTRUCTURE;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, RADIATION-INDUCED; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RADIOTHERAPY; SALVAGE THERAPY;

EID: 0034048889     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009058506     Document Type: Article

References (30)

1. Grunwald H, Rosner F (1982). Acute myeloid leukemia following treatment of Hodgkin's disease. Cancer, 50, 676-683.
2. Preisler H, Early A and Raza A (1983). Therapy of secondary acute nonlymphocyite leukemia with cytarabine. New Engl J Med. 308, 21-24.
3. Michels SD, Mc Kenna RW and Arthur DC (1985). Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood, 65, 1364-1372.
4. Le Beau MM, Albain KS and Larson RA (1986). Clinical and cytogenetic correlations in 63 patients with therapy -related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristics abnormalities of chromosomes 5 and 7. J. Clin Oncol, 4, 325-345.
5. Kantarjian HM, Keating MJ and Walters RS (1986). Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic features. J Clin Oncol, 4, 1748-1757.
6. Hoyle CF, DeBastos M and Whestley K (1989). AML associated with previous cytotoxic therapy. MDS or myeloproliferative disorders. Results from the MRC's 9th trial. Br J Haematol, 72, 45-53.
7. Pedersen-Bjergaard J, Philip P and Larsen SO (1990). Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute non-lymphocytic leukemia. Blood, 76, 1083-1091.
8. Latagliata R (1496). Is aggressive chemotherapy the best choice for patience with acute non lymphocytic leukemia after myelodysplastic sindromes? Leuk Res. 20, 385-390.
9. Aul C (1997). Aggressive Chemotherapy in MDS: the Dusseldorf experience, Leuk Res., 21 (Suppl 1), 45 (abstract).
10. Archimhaud E, Charrin C and Magaud J-P (1998). Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint. leukemia, 12, 25-33.
11. Pagano L, Annino L and Ferrari A (1998). Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. Br J Haematol, 100, 669-676.
12. Pui CH, Ribeiro BC and Hancock ML (1991). Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med, 325, 1682-1687.
13. Estey EH (1998). Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica, 83, 543-549.
14. Wattel E (1998). Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein: results of a randomized study. Br J Haematol., 102, 1015-1024.
15. Leith CP, Kopecky KJ and Godwin JE (1996). AML in the elderly: stratification by MDRI phenotype, secondary vs. de novo status, and cytogenetics identifies patients with high complete remission(CR) rates. Proc. ASCO. 15, 359.
16. Kantarjian HM, Keating MJ and Walters RS (1986). The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer, 58, 924-927.
17. Quesnel B, Kantarjian HM and Bjiergaard JP(1986). Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol, 11, 2370-2379.
18. Pollicardo N, O'Brien S, Estey EH, Al-Bitar M., Pierce S, Keating M, Kantarjian HM (1996). Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution, Leukemiad, 10, 27-31.
19. Fenaux P (1991). Prognostic factor in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol, 77, 497-501.
20. De Witte T (1995). Intensive chemotherapy for poor prognosis myelodisplasia (MDS) and secondary acute myeloid leukaemia (sAML) following MDS of more than 6 months of duration. A pilot study by the Leukemia Cooperative Group of the European Organization for Research and Treatment in Cancer(EORTC-LCG). Leukemia. 11, 1805-1811.
21. Ito T (1994). Recovery of polyclonal haematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy. Leukemia, 8, 839-843.
22. Bernasconi C, Alessandrino EP and Bernasconi P (1998). Chemioterapia aggressiva con supporto di G-CSF nel trattamento delle sindromi mielodisplastiche(SMD) ad alto rischio e delle leucemie acute secondarie a SMD, Progressi in Ematologia Clinica, 17, 33-12.
23. Gardin C, Chaibi P and De Revel T (1947). Intensive chemotherapy with idarubiein, cytosine arabinoside and granulocyte colony-stimulating factor(G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Leukemia, 11, 16-21.
24. Ganser A (1997). Aggressive chemotherapy with G-CSF priming is effective for advanced myelodysplastic syndromes and high risk acute myeloid leukemia: early results. Trends Onco-Hematol, 5, 3-4.
25. Weiek JK, Kopecky KJ and Appelbaum FR (1997). A randomized investigation of high dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia Blood, 10(7), 2121-25.
26. Visani G, TOSI P, Zinzani PL and Tura S (1994). FLAG(fludarabine + High-Dose Cytarabine + G-CSF): an effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemia. Leukemia, 8(11), 1842-46.
27. De Witte T (1990). Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute leukaemia. Cancer. 66, 831-837.
28. Carella AM (1996). In vivo mobilization of Karyotipically normal pheripheral blood progenitor cells in High risk MDS. secondary or therapy-related acute myelogenous leukemia. Br J Haemat, 95, 127-130.
29. Laporte JP (1993). Autologous bone marrow transplantation with marrow purged by Mafosfamide in seven patients with myelodysplastic syndrome in transformation(AML-MDS): a pilot study. Leukemia, 7, 2030-2033.
30. De Witte T (1997). Autologous bone marrow transplantation for patients with myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS. Chronic and Acute Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood, 10, 3853-3857.